Core Viewpoint - Exagen Inc. has experienced significant stock performance, with a 42.6% increase over the past month and a 38.7% gain since the beginning of the year, outperforming the Zacks Medical sector and the Zacks Medical - Products industry [1] Financial Performance - Exagen has consistently exceeded earnings expectations, reporting an EPS of -$0.16 against a consensus estimate of -$0.36 in its last earnings report [2] - For the current fiscal year, Exagen is projected to have an EPS of -$1.03 on revenues of $57.05 million, reflecting a 23.13% change in EPS and an 8.57% change in revenues [3] - The next fiscal year forecasts an EPS of -$0.74 on revenues of $64.85 million, indicating a year-over-year change of 27.67% in EPS and 13.67% in revenues [3] Valuation Metrics - Exagen's current valuation metrics suggest it may be at a 52-week high, prompting a review of its future stock performance [4] - The Zacks Style Scores indicate Exagen has a Value Score of C, a Growth Score of B, and a Momentum Score of A, resulting in a combined VGM Score of B [6] Zacks Rank - Exagen holds a Zacks Rank of 2 (Buy), supported by favorable earnings estimate revisions from analysts, suggesting potential for further gains [7]

Momentum investing is essentially an exception to the idea of "buying low and selling high." Investors following this style of investing are usually not interested in betting on cheap stocks and waiting long for them to recover. Instead, they believe that "buying high and selling higher" is the way to make far more money in lesser time. Everyone likes betting on fast-moving trending stocks, but it isn't easy to determine the right entry point. These stocks often lose momentum when their future growth potent ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2024 ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Commission File Number: 001-39049 EXAGEN INC. (Exact name of registrant as specified in its charter) Delaware 20-0434866 (State or Other Jurisdiction of Incorporation or Organization)(I.R.S. Em ...

Exagen Inc. Reports Strong Second Quarter 2024 Results: Raises Guidance due to Record Performance August 5, 2024 Carlsbad, Calif., – Exagen Inc. (Nasdaq: XGN), a leading provider of autoimmune testing solutions, today reported financial results for the quarter ended June 30, 2024. Highlights: • Recognized record total revenue of $15.1 million in the second quarter of 2024. • Delivered gross margin of 60.1% in the second quarter of 2024, compared to a gross margin of 58.7% in the second quarter of 2023. • AV ...

CARLSBAD, Calif., Aug. 05, 2024 (GLOBE NEWSWIRE) -- Exagen Inc. (NASDAQ:XGN), a leading provider of autoimmune testing solutions, today reported financial results for the quarter ended June 30, 2024. Highlights: Recognized record total revenue of $15.1 million in the second quarter of 2024. Delivered gross margin of 60.1% in the second quarter of 2024, compared to a gross margin of 58.7% in the second quarter of 2023. AVISE® CTD trailing twelve-month average selling price (ASP) of $401, a 25.3% increase ove ...

CARLSBAD, Calif., Aug. 02, 2024 (GLOBE NEWSWIRE) -- Exagen Inc. (Nasdaq: XGN), a leading provider of autoimmune testing solutions, today announced its participation in the Canaccord Genuity 44th Annual Growth Conference, which takes place August 13-15, 2024, at the InterContinental Boston Hotel in Boston, MA. John Aballi, Exagen's President and Chief Executive Officer will participate in a fireside chat on Wednesday, August 14th, at 2:30 PM ET. Interested parties may access the webcast of the presentation u ...

CARLSBAD, Calif., Aug. 02, 2024 (GLOBE NEWSWIRE) -- Exagen Inc. (Nasdaq: XGN), a leading provider of autoimmune testing solutions, today announced its participation in the Canaccord Genuity 44th Annual Growth Conference, which takes place August 13-15, 2024, at the InterContinental Boston Hotel in Boston, MA. John Aballi, Exagen's President and Chief Executive Officer will participate in a fireside chat on Wednesday, August 14th, at 2:30 PM ET. Interested parties may access the webcast of the presentation u ...

CARLSBAD, Calif., Aug. 01, 2024 (GLOBE NEWSWIRE) -- Exagen Inc. (NASDAQ:XGN), a leading provider of autoimmune testing solutions announced today the appointment of Jeffrey G. Black, to the role of Chief Financial Officer (CFO), effective September 1, 2024. Mr. Black replaces Kamal Adawi, who will be stepping down, and John Aballi will act as interim CFO through the end of August. "I sincerely thank Kamal for his leadership and numerous contributions to Exagen over the past decade," said John Aballi, Preside ...

CARLSBAD, Calif., July 22, 2024 (GLOBE NEWSWIRE) -- Exagen Inc. (Nasdaq: XGN), a leading provider of autoimmune testing, will release financial results for the quarter ended June 30, 2024, before the market opens on Monday, August 5, 2024. John Aballi, Exagen's President and Chief Executive Officer, and Kamal Adawi, Chief Financial Officer, will host a conference call to review the Company's results at 8:30 AM ET (5:30 AM PT). Exagen is a leading provider of autoimmune testing and its purpose as an organiza ...

Exagen, Inc. (NASDAQ:XGN) Q1 2024 Earnings Conference Call May 13, 2024 8:30 AM ET Company Participants Ryan Douglas - Investor Relations John Aballi - President and Chief Executive Officer Kamal Adawi - Chief Financial Officer Conference Call Participants Mark Massaro - BTIG Kyle Mikson - Canaccord Genuity Dan Brennan - TD Cowen Operator Greetings, welcome to Exagen, Inc. First Quarter 2024 Earnings Call. At this time, all participants are in listen-only mode. A question-and-answer session will follow the ...